CLDX - Celldex Therapeutics, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
1,078
2,357
4,651
7,418
3,573
Operating expenses
Research development
74,037
82,258
53,311
42,534
42,672
Selling general and administrative
26,837
27,195
20,488
14,456
15,426
Total operating expenses
100,874
109,453
73,799
56,990
58,098
Operating income or loss
-99,796
-107,096
-69,148
-49,572
-54,525
Total other income/expenses net
-6,190
-5,229
-1,590
-11,375
3,647
Income before tax
-105,986
-112,325
-70,738
-60,947
-50,878
Income tax expense
0
0
-227
-1,167
0
Income from continuing operations
-105,986
-112,325
-70,511
-59,780
-50,878
Net income
-105,986
-112,325
-70,511
-59,780
-50,878
Net income available to common shareholders
-105,986
-112,325
-70,511
-59,780
-50,878
Basic EPS
-
-2.40
-1.64
-2.02
-3.51
Diluted EPS
-
-2.40
-1.64
-2.02
-3.51
Basic average shares
-
46,888
42,870
29,640
14,507
Diluted average shares
-
46,888
42,870
29,640
14,507
EBITDA
-
-107,096
-69,148
-49,572
-54,525